Month: September 2024

ST. GALLEN, Switzerland, Sept. 19, 2024 (GLOBE NEWSWIRE) — Sportradar (NASDAQ: SRAD) is set to further transform the betting landscape with the launch of micro markets, the next generation of in-play betting products, across leading sports, opening fresh revenue streams for operators. In a strategic move, Sportradar, in collaboration with Tennis Data Innovations (TDI), is introducing micro markets for ATP tennis matches this October. This exclusive partnership marks yet another step in offering bettors more granular and engaging wagering options in tennis.* Sportradar currently offers micro markets across other popular sports including soccer and table tennis. By leveraging advanced artificial intelligence (AI) and deep tennis data from TDI, Sportradar will offer operators a cutting-edge solution that processes hundreds of thousands...

BYMA to base its entire post-trade ecosystem on Nasdaq technology Argentinian exchange group to adopt Nasdaq’s real-time clearing platform, expanding the companies’ existing Central Securities Depository partnership The clearing platform will enhance capacity and connectivity whilst reducing operational complexity NEW YORK and BUENOS AIRES, Argentina, Sept. 19, 2024 (GLOBE NEWSWIRE) — Nasdaq (Nasdaq: NDAQ) and BYMA, Argentina’s leading stock exchange group, today announced a significant expansion of their technology partnership that will see BYMA base its entire post-trade ecosystem on Nasdaq technology. Under the terms of the agreement BYMA will adopt Nasdaq’s real-time clearing platform at its central counterparty clearinghouse (CCP), complementing Nasdaq’s existing technology partnership with Caja de Valores, Argentina’s central...

SPARK Matrix_APA_2024Spark Matrix for Accounts Payable Automation 2024Quadient (Euronext Paris: QDT), a global automation platform powering secure and sustainable business connections, announced today it has been recognized as a Technology Leader in the “SPARK Matrix: Accounts Payable Automation” report, a detailed analysis of the accounts payable (AP) automation market by independent analyst firm QKS Group. The recognition comes on the heels of Quadient also being named a Technology Leader in the “2024 SPARK Matrix: Accounts Receivable (AR) Applications” report, which published in May. This marks the second year in a row that Quadient has been named a leader in both AP and AR in the SPARK Matrix reports. Cloud-based Quadient AP automates end-to-end AP processes for finance teams and is part of Quadient’s digital automation platform,...

EPSO-G, a group of energy transmission and exchange companies (company code 302826889), with its registered office located at Laisvės pr. 10, Vilnius, Lithuania. From 18 September 2024 by the decision of the sole shareholder of EPSO-G, the Ministry of Energy of the Republic of Lithuania, a new independent member of the board, Rasa Balevičienė, was appointed to the board of EPSO-G. The EPSO-G group of companies consists of the holding company EPSO-G and its six direct subsidiaries Amber Grid, Baltpool, Energy cells, EPSO-G Invest, Litgrid and Tetas. EPSO-G and its Group companies also hold shares in GET Baltic, Baltic RCC OÜ and TSO Holding AS. The rights and obligations of the sole shareholder of EPSO-G are exercised by the Ministry of Energy of the Republic of Lithuania. For more information, contactGediminas Petrauskas, communication...

London (UK), September 19 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments, today announces that the United States Patent and Trademark Office (USPTO) has issued a patent to the company offering broad protection of the mode of action underlying its oncology and onco-dermatologic therapeutic candidates. The patent protects the use of Vidac’s new chemical entities to detach the hexokinase2 isozyme from the mitochondrial VDAC pores to reverse the hyperglycolytic metabolism of cancer cells. Vidac’s clinical studies have shown that this has the potential to halt cancer cell proliferation, restore programmed cell death (apoptosis) and suppress the immunosuppressive qualities of the tumor microenvironment. “This...

ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrated reduction in disease progression, reduced risk of relapse and rapid onset of action VYVGART Hytrulo is first and only neonatal Fc receptor (FcRn) blocker FDA-approved to treat CIDP September 19, 2024 – 7:00 am CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced publication in The Lancet Neurology of the pivotal ADHERE Study, the largest clinical trial to date in chronic inflammatory demyelinating polyneuropathy (CIDP). CIDP is a rare, debilitating, often progressive, immune-mediated neuromuscular disorder of the peripheral nervous system....

Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza from an infected person to household members This is the first time that any antiviral used in the treatment of a respiratory viral illness has demonstrated a transmission reduction benefit in a global phase III study Reducing the spread of infection in the household could help limit transmission within communities and societies, easing the burden of both seasonal and pandemic influenza on healthcare systemsBasel, 19 September – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline results of the phase III CENTERSTONE study of Xofluza® (baloxavir marboxil), an antiviral, showing a reduction in the transmission of influenza viruses. The study met its primary endpoint, demonstrating that a single, oral dose of Xofluza taken...

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 19, 2024 – Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its provisional half-year and second quarter net results have increased significantly in 2024 compared to 2023 and first quarter 2024 results primarily due to the sale of part of its business to Neurosterix Pharma Sàrl on April 2, 2024. The provisional result amount to a net gain of CHF 9.8 million for the six-month period ended June 30, 2024 compared to a net loss of CHF 5.1 million for the six-month period ended June 30, 2023. The increase of CHF 14.9 million is primarily due to the gross proceeds of CHF 5.0 million received in cash from...

Tonner Drones Convenes GM and Expands Strategy Cannes, 18 September 2024 18:00, Tonner Drones (the “Company”) is pleased to announce that it is convening a shareholders’ general meeting to be held on October 21th (the “GM”) so that shareholders can vote on several important resolutions including the mandate to expand its strategy. Mandate Strategy During the GM, shareholders will be asked to vote on a mandate to implement a new strategy and amend the articles of association accordingly. The Company has successfully completed a restructuring and refinancing process by, among other items, settling various financing contracts and terminating all equity-lines. The Company’s new management is convinced that it can also help other listed companies to escape similar stifling financing structures. The Company is in the position to advise the...